Liquid Biopsy to Enable Diagnostics and Monitoring for Immune-mediated Lymphoproliferative Disorders

Launched by UNIVERSITY HOSPITAL, GENEVA · Mar 24, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to detect and monitor immune-mediated lymphoproliferative disorders (ILD), which are rare and serious conditions that can occur after organ transplants or in people with certain autoimmune disorders. The study will use a method called liquid biopsy to analyze small pieces of genetic material in the blood, which can help doctors identify the disease earlier and track how well treatment is working. The goal is to improve how these conditions are managed and possibly find better treatment options for patients.

To participate in this trial, you need to be diagnosed with an ILD according to specific guidelines, and you cannot have a non-immune-related lymphoproliferative disorder or be HIV-positive. If you join the study, you will undergo tests to monitor your condition using this new blood test, and you will be contributing to important research that could lead to better care for people with ILD in the future. The trial is currently recruiting participants of all ages and genders.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Any patient with a diagnosis of ILD defined by the World Health Organization (WHO HAEM 5)(e.g. post-transplant setting, X-link, concomitant auto-immune disorders)
• Exclusion Criteria:
• • Lymphoproliferative disorders non immune-mediated
• • Lymphoproliferative disorders occurring in the context of a concomitant human immunodeficiency virus (HIV) infection